SCHEMBL23770628

SCHEMBL23770628

FC(F)(F)c1ccc(NSc2cccc(N3CCNCC3)n2)nc1-c1ccccc1C1CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.42
CYP2C9 P11712 1/20 0.42
ADRB2 P07550 2/20 0.39
CYP2C19 P33261 1/20 0.38
HTR2C P28335 4/20 0.36
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
HTR3E A5X5Y0 2/20 0.34
HTR3B O95264 2/20 0.34
HTR3A P46098 2/20 0.34
HTR3D Q70Z44 2/20 0.34
HTR3C Q8WXA8 2/20 0.34
TRPA1 O75762 1/20 0.33
HTR6 P50406 2/20 0.33
KARS1 Q15046 1/20 0.33
HTR2A P28223 1/20 0.32
CHEK1 O14757 1/20 0.32
CDK7 P50613 1/20 0.32
EPHX2 P34913 1/20 0.32
RBP4 P02753 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770686 0.88 RBP4 (0.35) CYP1A2CYP2C9CYP2C19ALDH1A1KDM4E
SCHEMBL23770663 0.87 CYP1A2 (0.43) CYP1A2CYP2C9ADRB2CYP2C19HTR2C
SCHEMBL23770810 0.86 MPL (0.32) TRPA1RBP4CCNT1CCNKCCNE1
SCHEMBL23770560 0.86 CYP1A2 (0.45) CYP1A2CYP2C9ADRB2CYP2C19HTR2C
SCHEMBL23770665 0.84 TLR7 (0.36) ALDH1A1KDM4EUSP2MAPK1HSD17B10
SCHEMBL23770498 0.84 CHRNA7 (0.31) TRPA1
SCHEMBL23770453 0.84 CYP1A2 (0.40) CYP1A2CYP2C9ADRB2CYP2C19ALDH1A1
SCHEMBL23770606 0.84 ADRB2 (0.43) CYP1A2CYP2C9ADRB2CYP2C19ALDH1A1
SCHEMBL23770597 0.83 RBP4 (0.33) TRPA1RBP4
SCHEMBL22338280 0.82 TRPA1 (0.36) HTR2CTRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed